Status:
COMPLETED
Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Atherosclerosis
Eligibility:
All Genders
18-65 years
Brief Summary
This is a longitudinal observational study of HIV-infected patients and HIV-negative control patients that is being conducted to learn more about immunologic factors, inflammation, and cardiovascular ...
Detailed Description
This proposal is currently approved by CHR (#H9577-18534-03C, exp date 3/26/04); the purpose of this new application is to split the currently approved protocol into a separate protocol with a separat...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Stable antiretroviral therapy for at least 12 months, and have no immediate plans to alter therapy.
- All plasma HIV RNA levels within the past year must be below conventional levels of detection (\< 50 copies RNA/mL), although isolated single values \> 50 but \< 1000 copies will be allowed if they were preceded and followed by undetectable viral load determinations.
- Ability to provide reliable history of HIV medications or has received the majority of medical care from San Francisco General Hospital with available records of medical treatment
Exclusion
Key Trial Info
Start Date :
July 1 2003
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2021
Estimated Enrollment :
579 Patients enrolled
Trial Details
Trial ID
NCT01519141
Start Date
July 1 2003
End Date
January 1 2021
Last Update
November 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California San Francisco, San Francisco General Hospital
San Francisco, California, United States, 94110